Best Life Sciences Platforms and Tools Companies in Jiangsu, China
The 50 best Life Sciences Platforms and Tools companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CF PharmTech.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Jiangsu
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Aijie Boya Developer of laboratory equipment for research applications | — | — | Funding Raised | 2021 | — | 29 | — | — |
| 2 | Biomics Biotechnologies Developing RNAi-based drugs for range of diseases | — | — | Unfunded | 2006 | York Zhu Founder & CEO | — | 41 patents Lipid-based nucleic acid delivery systems for antiviral and dermatological therapeutics | — |
| 3 | Boyalife Group Provider of services for genomics, drug discovery, and regenerative medicine | — | — | Unfunded | 2009 | Xiaochun Xu Co-Founder & Chairman | — | 2 patents Peptide-based anti‑aging therapeutics and devices for live cell separation | — |
| 4 | Changzhou Hekang Medical Instruments Consumables for hospitals and diagnostic Industry | — | — | Unfunded | 2005 | Waley Mao CEO | — | — | — |
| 5 | CT Bioscience Provider of genomics services to the life science industry | — | — | Deadpooled | 2009 | Xiangdong Lei CEO | — | 16 patents Bispecific antibody therapeutics targeting tumor antigens for cancer immunotherapy | — |
| 6 | Etta Biotech Developer of electroporation machines and consumables for research professionals | — | — | Funding Raised | 2014 | Dai Xiaobing CEO | 17 | — | — |
| 7 | First Dimension BioSciences Service provider in clinical diagnosis and prognostic monitoring | — | — | Deadpooled | 2015 | Y Tom Tang Co-Founder & CEO | — | — | — |
| 8 | Heading (Nanjing) Pharmtechnologies Provider of services for commercial production of APIs and intermediates | — | — | Funding Raised | 2013 | Zhang Wenqi CEO | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Jiangsu
#1
Seed · Suzhou, Jiangsu · founded 2020$10Mraised▾
Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech and pharmaceutical industries. It utilises the power of Large Language Models specifically trained on biological languages to discover and develop effective drugs.
- Dec 2025Seed$10M
#2
Series C · Wuxi, Jiangsu · founded 2008$1.4Mraised▾
Developer of disease diagnostic reagents. The company focuses on the development and labeling services of radioisotope-labeled compounds such as C14 and detection reagents for disease detection by tandem mass spectrometry.
- Oct 2025Series C$14M
- Oct 2022Seed$1.4M
#3
Series B · Suzhou, Jiangsu · founded 2019 · 500 employees$130Mraised▾
Provider of an in vitro assay platform for diagnostic solutions. The company's technology can be used for early screening, diagnosis, treatment/monitoring and management of the minimal residual disease. The technology can be used in a variety of diseases such as infectious disease, cancer, maternal and fetal health, and chronic disease.
- Jan 2022Series B$100M
- Dec 2020Series A$30M
#4
Series B · Zhangjiagang, Jiangsu · founded 2014 · 80 employees$23.5Mraised▾
Developer of bio-detection chips and electronic biochemical sensors. The company develops and manufactures bio-detection chips and electronic biochemical sensors. Offerings include pH/ion chips and nanoelectrodes. It uses nano-electronic sensors and nano-materials technology to develop its products. The products have applications in the medical and diagnostics industry. Also, provide digital PCR and genetic (DNA) testing services.
- Sep 2023Series B—
- Apr 2022Series B$23.5M
- Jan 2021Series B—
- Aug 2018Series B—
#5
Public · Suzhou, Jiangsu · founded 2019 · 318 employees$205Mraised▾
Transcenta is involved in research and development of antibody-based therapeutics. It is involved in manufacturing the novel antibody for patients. It also offers a translationla research and clinical development center.
- Dec 2020Series C$105M
- Jan 2020Series B$100M
- Aug 2019Series A—
#6
Public · Wuxi, Jiangsu · founded 2007 · 550 employees$206.4Mraised▾
CF PharmTech is a Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company, and CDMO. The company develops formulations and devices required for the metered-dose inhaler, inhalation powder, nasal spray, and blow-fill-seal products. The disease areas focused on are Rhinitis, Asthma, and COPD, and also other respiratory diseases. The company develops new formulations for existing and new substances, new delivery systems for existing and new APIs, and working with independent research teams to develop new products.
- Jul 2020Series F$50.9M
- Jan 2020Series E$90.5M
- Aug 2017Series D$65M
#7
Public · Nanjing, Jiangsu · founded 2018 · 10 employees$81.9Mraised▾
Provider of humanized models and drug screening technologies. It offers research application for animal models for different drug and disease metabolism, functional analysis and evaluation, animal model like trasgenic mouse, ES gene editing and others. It also offers other technical services like cell-line, biological sample refrigeration and others.
- Sep 2020Series B$58.5M
- Jul 2019Series A$23.4M
#8
Series B · Suzhou, Jiangsu · founded 2018$30.9Mraised▾
Developer of droplet digital PCR. The products include the DQ24 digital PCR system, SAG-100 droplet workstation, and rapid qPCR which are used for cancer biomarker studies, gene expression analysis, quantification for the NGS library, and others. The system is based on vibroject droplet generation technology in which generates stable microdroplets.
- Sep 2021Series B$30.9M
#9
Acqui-Hired · Suzhou, Jiangsu · founded 2017 · 250 employees$72Mraised▾
Developer and manufacturer of biologic products. They offer services including cell line development, upstream development, downstream development, formulation development, process development, analytical development, and stability studies for pre-clinical and clinical stage biologics manufacturing.
- Apr 2018Series B$34M
- Jan 2018Series A$38M
#10
Public · Suzhou, Jiangsu · founded 2010 · 488 employees$36.5Mraised▾
Developer of NGS-based diagnostic solutions for neonatal. The company has a range of pre-pregnancy tests, pre-implantation tests, non-invasive prenatal tests, and early/neonatal genetic screening tests, all marketed under the Basecare brand. The company is supported by Daan Gene Corp. of Sun Yat-Sen University.
- May 2020Series C$21.1M
- Sep 2017Series B$15.4M
- Series A—
#11
Public · Nanjing, Jiangsu · founded 2014$29.8Mraised▾
Nanjing Wei Li Zhi Bo Biotechnology is involved in research and development of a platform for tumor immunotherapy. The company has the intellectual property for single-target antibody and bispecific antibody for drug development technology platform. The leading candidates of the company anti-LAG3 and anti TIM3 are in the pre-clinical stage of a clinical study and the other candidates are in cell line stage of a clinical study and are effective against solid tumor.
- Oct 2020Series C$29.8M
#12
Series A · Suzhou, Jiangsu · founded 2010$29.5Mraised▾
Developer of drug discovery platform. The company performs cross high throughput screening of human protein chips, which express hundreds of human genes that possibly act as drug targets and use their proprietary computational chemistry method for the discovery of novel compounds.
- Jul 2019Series A$14.5M
- Dec 2017Series A$15M
- Sep 2017Seed—
- Mar 2017Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Jiangsu is moving
A read on the academic research around Bioinformatics in Jiangsu — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 255 papers.
- Jiangsu University103
- Jiangsu Province Hospital44
- Affiliated Hospital of Jiangsu University35
- Jiangsu Cancer Hospital23
- Northern Jiangsu People\'s Hospital17
- Transcriptome1→8
- Cancer1→5
- Biomarker1→4
- Microvesicles1→5
- Immune system11
- Immunotherapy7
- Precision medicine6
- Cancer5
- Biomarker5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.